Osiris Therapeutics, Inc.
OSIRIS THERAPEUTICS, INC. (Form: NT 10-Q, Received: 08/10/2017 16:07:27)

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 12b-25

 

NOTIFICATION OF LATE FILING

 

 

 

SEC File Number: 001-32966

CUSIP Number: 68827R 10 8

 

(Check one):

 

o  Form 10-K

o  Form 20-F

o  Form 11-K

x  Form 10-Q

o  Form 10-D

 

 

o  Form N-SAR

o  Form N-CSR

 

 

 

 

 

 

 

 

 

 

 

 

For Period Ended:

June 30, 2017

 

 

o   Transition Report on Form 10-K

 

 

 

 

o   Transition Report on Form 20-F

 

 

 

 

o   Transition Report on Form 11-K

 

 

 

 

o   Transition Report on Form 10-Q

 

 

 

 

o   Transition Report on Form N-SAR

 

 

 

 

For the Transition Period Ended:

 

 

Read Instructions (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:


 

PART I — REGISTRANT INFORMATION

 

OSIRIS THERAPEUTICS, INC.

Full Name of Registrant

 

 

Former Name if Applicable

 

7015 Albert Einstein Drive

Address of Principal Executive Office (Street and Number)

 

Columbia, Maryland 21046

City, State and Zip Code

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

 

(a)

The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense

o

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 

(c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III — NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

Osiris Therapeutics, Inc. (the “ Company ”) is unable to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 (the “ Q2 2017 Quarterly Report ”) by the prescribed due date of August 9, 2017.

 

The Company is working diligently to complete its previously announced restatement of prior period financial statements and complete its 2015 and 2016 financial statements as well as its first quarter 2017 (“Q1 2017”) and second quarter 2017 (“2Q 2017”) financial statements, so that the Company will be in a position to bring its filings with the Securities and Exchange Commission (“SEC”) up to date.

 

The Company will require additional time to complete its 2015 and 2016 financial statements and its unaudited Q1 2017 and Q2 2017 financial statements.  The specific date of the filing of the Q2 2017 Quarterly Report is not yet known, but the Company currently does not expect to file the Q2 2017 Quarterly Report within the extension period of five calendar days provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

 



 

PART IV — OTHER INFORMATION

 

(1)

Name and telephone number of person to contact in regard to this notification

 

Linda Chang

 

443

 

545-1800

 

(Name)

 

(Area Code)

 

(Telephone Number)

 

 

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

 

 

 

 

 

o  Yes     x  No

 

Annual Report on Form 10-K for the period ended December 31, 2015

Quarterly Report on Form 10-Q for the period ended March 31, 2016

Quarterly Report on Form 10-Q for the period ended June 30, 2016

Quarterly Report on Form 10-Q for the period ended September 30, 2016

Annual Report on Form 10-K for the period ended December 31, 2016

Quarterly Report on Form 10-Q for the period ended March 31, 2017

 

 

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

 

 

 

 

 

 

 

x  Yes     o  No

 

 

 

 

 

 

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 

 

Due to the ongoing work of the Company described above, the Company is unable to quantify or provide a reasonable estimate of the changes in results of operations for the quarter ended June 30, 2017 until such review is complete.

 

Forward-Looking Statements

 

Certain matters discussed in this Form 12b-25 constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are based on management’s current beliefs, assumptions and expectations regarding future events, which in turn are based on information currently available to management. Such forward-looking statements include statements about the Company’s ongoing work on the restatement, completion of amendments to prior SEC filings, timing to complete an audit of the Company’s 2015 and 2016 financial statements and a review of the Company’s Q1 2017 and Q2 2017 financial statements, anticipated timing of the filing of its Q2 2017 Quarterly Report, and its ability to quantify or provide estimates to changes in results of operations for the same period.  We caution you not to place undue reliance on any such forward-looking statements.  Several factors could cause actual results to differ materially from those expressed in or contemplated by the forward-looking statements. Such factors include, but are not limited to, the identification of additional accounting adjustments from the Company’s ongoing work on the Company’s financial statements, changes in the scope or focus of the accounting adjustments in the restatement of 2015 interim periods, the timing of completion of the audit of our 2015 and 2016 financial statements by our new independent registered public accounting firm, the timing of completion of the review of our unaudited Q1 2017 and Q2 2017 financial statements by our new independent registered public accounting firm, or delays in the preparation of our Annual Report on Form 10-K for the year ended December 31, 2015, our Quarterly Report on Form 10-Q for the period ended March 31, 2016, our Quarterly Report on Form 10-Q for the period ended June 30, 2016, our Quarterly Report on Form 10-Q for the period ended September 30, 2016, our Annual Report on Form 10-K for the year ended December 31, 2016, our Quarterly Report on Form 10-Q for the period ended March 31, 2017 or our Q2 2017 Quarterly Report.  Other risk factors affecting the Company are discussed in detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K/A for the year ended December 31, 2014. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

 



 

OSIRIS THERAPEUTICS, INC.


(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:

August 10, 2017

 

By:

/s/ Linda Chang

 

 

 

 

Name: Linda Chang

 

 

 

 

Title: Chief Financial Officer

 

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

 

 

ATTENTION

 

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).